Document is current
Any future updates will be listed below
-
Authors
Wueest, Stephan https://orcid.org/0000-0002-0176-8906
Scaffidi, Chiara
van Krieken, Pim P. https://orcid.org/0000-0002-0501-3076
Konrad, Nils K.
Koch, Christian https://orcid.org/0009-0000-0681-4265
Lempesis, Ioannis G.
Fullin, Jonas
Manolopoulos, Konstantinos N.
Böttcher, Steffen
Goossens, Gijs H. https://orcid.org/0000-0002-2092-3019
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Konrad, Daniel https://orcid.org/0000-0001-9067-4356
- License Information
-
More Information
Article History
Received: 19 July 2024
Revised: 15 November 2024
Accepted: 21 November 2024
First Online: 1 December 2024
Competing interests
: The authors declare the following relationships to entities: Novo Nordisk (DK), Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis, Sanofi, Pfizer (MB), none (SW, CS, PPvK, NKK, CK, IGL, JF, KNM, SB, GHG).
